Scientists test 'Smart Bomb' drug combo against aggressive leukemia
NCT ID NCT06034470
Summary
This early-stage study is testing a new combination treatment for adults newly diagnosed with high-risk forms of acute myeloid leukemia (AML) and related blood cancers. The trial combines a standard chemotherapy regimen (FLAG-Ida) with an experimental targeted drug called pivekimab sunirine (PVEK). PVEK is designed to act like a 'smart bomb,' attaching specifically to cancer cells and delivering a chemotherapy payload directly to them. The main goals are to find the safest dose of PVEK when given with chemotherapy and to see if this combination is effective at putting the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.